Third US patent on Israeli Teva's MS drug Copaxone invalidated

By REUTERS
September 1, 2016 22:14

NEW YORK- US patent officials on Thursday invalidated a third patent covering Israel's Teva Pharmaceutical Industries' $4 billion multiple sclerosis treatment Copaxone, after canceling two other patents on the drug last week.

The ruling came in a challenge at the US Patent and Trademark Office by Mylan NV, which is trying to bring out a generic version of the 40-milligram injectable drug, taken three times a week. According to the US Food and Drug Administration, Copaxone is protected by five patents in total.


Related Content

Breaking news
April 27, 2018
Report: Acting Armenian PM rejects talks with opposition leader

By REUTERS

Israel Weather
  • 15 - 24
    Beer Sheva
    17 - 22
    Tel Aviv - Yafo
  • 13 - 19
    Jerusalem
    16 - 22
    Haifa
  • 20 - 28
    Elat
    17 - 27
    Tiberias